Please login to the form below

Not currently logged in
Email:
Password:

Acquisition

This page shows the latest Acquisition news and features for those working in and with pharma, biotech and healthcare.

GSK’s PD-1 inhibitor dostarlimab shows updated promise in dMMR solid tumours

GSK’s PD-1 inhibitor dostarlimab shows updated promise in dMMR solid tumours

GSK gained dostarlimab from its $5.1bn acquisition of cancer specialist Tesaro, as well as PARP inhibitor Zejula (niraparib), which is approved across a number of indications including ovarian, fallopian tube

Latest news

  • Sanofi gains access to antibody tech with Kymab acquisition Sanofi gains access to antibody tech with Kymab acquisition

    The acquisition will also give Sanofi access to new antibody technologies and research capabilities, the company said in a statement. ... The Kymab acquisition is the first acquisition agreed by Sanofi in 2021, following a string of deals made throughout

  • Servier to acquire Agios’ oncology business in $1.8bn deal Servier to acquire Agios’ oncology business in $1.8bn deal

    area. “The strategic acquisition of Agios’ oncology business, including its precision medicine portfolio and pipeline, is aligned with our ambition to become a recognised player in oncology and further supports our ... Aside from strengthening its

  • Lilly picks up gene therapy programme in $1bn Prevail Therapeutics acquisition deal Lilly picks up gene therapy programme in $1bn Prevail Therapeutics acquisition deal

    For Lilly, the acquisition will extend its focus into developing gene therapies, establishing an in-house gene therapy programme ‘anchored’ by Prevail’s current portfolio and AAV-based technology. ... We look forward to completing the proposed

  • AstraZeneca to acquire Alexion for $39bn AstraZeneca to acquire Alexion for $39bn

    The acquisition is one of the largest deals announced this year and is also AZ’s largest corporate acquisition ever, according to Reuters. ... This acquisition allows us to enhance our presence in immunology,” said Pascal Soriot, chief executive

  • Boehringer spends €1.18bn to acquire NBE-Therapeutics Boehringer spends €1.18bn to acquire NBE-Therapeutics

    The acquisition is expected to close, subject to customary closing conditions, during the first quarter of 2021. ... This acquisition is a further example of Boehringer Ingelheim’s long-term strategy to enhance our position as an innovator of novel

More from news
Approximately 198 fully matching, plus 1,229 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 74 fully matching, plus 93 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 119 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 8 fully matching, plus 73 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

Emre Vural
Sourcing R&D innovation: why pharma companies need to evolve their business models
Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
Gilead Headquarters
The search for effective drug treatments for COVID-19
PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...

Infographics